|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:TSPAN13-AHR (FusionGDB2 ID:94039) |
Fusion Gene Summary for TSPAN13-AHR |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: TSPAN13-AHR | Fusion gene ID: 94039 | Hgene | Tgene | Gene symbol | TSPAN13 | AHR | Gene ID | 27075 | 196 |
| Gene name | tetraspanin 13 | aryl hydrocarbon receptor | |
| Synonyms | NET-6|NET6|TM4SF13 | RP85|bHLHe76 | |
| Cytomap | 7p21.1 | 7p21.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | tetraspanin-13tetraspan NET-6transmembrane 4 superfamily member 13transmembrane 4 superfamily member tetraspan NET-6tspan-13 | aryl hydrocarbon receptorAH-receptorah receptoraromatic hydrocarbon receptorclass E basic helix-loop-helix protein 76 | |
| Modification date | 20200313 | 20200322 | |
| UniProtAcc | . | A9YTQ3 | |
| Ensembl transtripts involved in fusion gene | ENST00000262067, ENST00000466195, | ENST00000242057, ENST00000492120, | |
| Fusion gene scores | * DoF score | 5 X 4 X 3=60 | 4 X 4 X 2=32 |
| # samples | 5 | 4 | |
| ** MAII score | log2(5/60*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/32*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: TSPAN13 [Title/Abstract] AND AHR [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | AHR(17338953)-TSPAN13(16815836), # samples:3 TSPAN13(16793655)-AHR(17349559), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | TSPAN13-AHR seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. TSPAN13-AHR seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF. TSPAN13-AHR seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. TSPAN13-AHR seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. AHR-TSPAN13 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF. AHR-TSPAN13 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. AHR-TSPAN13 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. AHR-TSPAN13 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | AHR | GO:0006355 | regulation of transcription, DNA-templated | 10395741 |
| Tgene | AHR | GO:0006357 | regulation of transcription by RNA polymerase II | 15681594 |
| Tgene | AHR | GO:0006366 | transcription by RNA polymerase II | 10395741 |
| Tgene | AHR | GO:0009410 | response to xenobiotic stimulus | 7961644 |
| Tgene | AHR | GO:0009636 | response to toxic substance | 7961644 |
| Tgene | AHR | GO:0010468 | regulation of gene expression | 15681594 |
| Tgene | AHR | GO:0019933 | cAMP-mediated signaling | 17329248 |
| Tgene | AHR | GO:0030888 | regulation of B cell proliferation | 15681594 |
| Tgene | AHR | GO:0071320 | cellular response to cAMP | 17329248 |
| Tgene | AHR | GO:1904322 | cellular response to forskolin | 17329248 |
| Tgene | AHR | GO:1904613 | cellular response to 2,3,7,8-tetrachlorodibenzodioxine | 17329248 |
| Fusion gene breakpoints across TSPAN13 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across AHR (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | OV | TCGA-20-1685 | TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + |
Top |
Fusion Gene ORF analysis for TSPAN13-AHR |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000262067 | ENST00000242057 | TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + |
| 5CDS-intron | ENST00000262067 | ENST00000492120 | TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + |
| intron-3CDS | ENST00000466195 | ENST00000242057 | TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + |
| intron-intron | ENST00000466195 | ENST00000492120 | TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for TSPAN13-AHR |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + | 0.000525028 | 0.99947494 |
| TSPAN13 | chr7 | 16793655 | + | AHR | chr7 | 17349559 | + | 0.000525028 | 0.99947494 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for TSPAN13-AHR |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | AHR |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Mediates dioxin toxicity and is involved in regulation of cell growth and differentiation. Represses the transcription activity of AHR by competing with this transcription factor for heterodimer formation with the ARNT and subsequently binding to the xenobiotic response element (XRE) sequence present in the promoter regulatory region of variety of genes. Represses CYP1A1 by binding the XRE sequence and recruiting ANKRA2, HDAC4 and/or HDAC5. Autoregulates its expression by associating with its own XRE site. {ECO:0000269|PubMed:17890447, ECO:0000269|PubMed:18172554}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for TSPAN13-AHR |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for TSPAN13-AHR |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for TSPAN13-AHR |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for TSPAN13-AHR |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | AHR | C0006142 | Malignant neoplasm of breast | 2 | CTD_human |
| Tgene | AHR | C0019209 | Hepatomegaly | 2 | CTD_human |
| Tgene | AHR | C0021368 | Inflammation | 2 | CTD_human |
| Tgene | AHR | C0023895 | Liver diseases | 2 | CTD_human |
| Tgene | AHR | C0023903 | Liver neoplasms | 2 | CTD_human |
| Tgene | AHR | C0027626 | Neoplasm Invasiveness | 2 | CTD_human |
| Tgene | AHR | C0028754 | Obesity | 2 | CTD_human |
| Tgene | AHR | C0030297 | Pancreatic Neoplasm | 2 | CTD_human |
| Tgene | AHR | C0043094 | Weight Gain | 2 | CTD_human |
| Tgene | AHR | C0086565 | Liver Dysfunction | 2 | CTD_human |
| Tgene | AHR | C0149721 | Left Ventricular Hypertrophy | 2 | CTD_human |
| Tgene | AHR | C0333641 | Atrophic | 2 | CTD_human |
| Tgene | AHR | C0345904 | Malignant neoplasm of liver | 2 | CTD_human |
| Tgene | AHR | C0346647 | Malignant neoplasm of pancreas | 2 | CTD_human |
| Tgene | AHR | C0678222 | Breast Carcinoma | 2 | CTD_human |
| Tgene | AHR | C1257931 | Mammary Neoplasms, Human | 2 | CTD_human |
| Tgene | AHR | C1458155 | Mammary Neoplasms | 2 | CTD_human |
| Tgene | AHR | C4704874 | Mammary Carcinoma, Human | 2 | CTD_human |
| Tgene | AHR | C0000786 | Spontaneous abortion | 1 | CTD_human |
| Tgene | AHR | C0000822 | Abortion, Tubal | 1 | CTD_human |
| Tgene | AHR | C0003865 | Arthritis, Adjuvant-Induced | 1 | CTD_human |
| Tgene | AHR | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| Tgene | AHR | C0004153 | Atherosclerosis | 1 | CTD_human |
| Tgene | AHR | C0004943 | Behcet Syndrome | 1 | CTD_human |
| Tgene | AHR | C0005612 | Birth Weight | 1 | CTD_human |
| Tgene | AHR | C0005683 | Urinary Bladder Calculi (disorder) | 1 | CTD_human |
| Tgene | AHR | C0005974 | Bone Resorption | 1 | CTD_human |
| Tgene | AHR | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| Tgene | AHR | C0009319 | Colitis | 1 | CTD_human |
| Tgene | AHR | C0011616 | Contact Dermatitis | 1 | CTD_human |
| Tgene | AHR | C0018273 | Growth Disorders | 1 | CTD_human |
| Tgene | AHR | C0018798 | Congenital Heart Defects | 1 | CTD_human |
| Tgene | AHR | C0018800 | Cardiomegaly | 1 | CTD_human |
| Tgene | AHR | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| Tgene | AHR | C0020538 | Hypertensive disease | 1 | CTD_human |
| Tgene | AHR | C0020564 | Hypertrophy | 1 | CTD_human |
| Tgene | AHR | C0020578 | Hyperventilation | 1 | CTD_human |
| Tgene | AHR | C0021364 | Male infertility | 1 | CTD_human |
| Tgene | AHR | C0021655 | Insulin Resistance | 1 | CTD_human |
| Tgene | AHR | C0023890 | Liver Cirrhosis | 1 | CTD_human |
| Tgene | AHR | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| Tgene | AHR | C0025517 | Metabolic Diseases | 1 | CTD_human |
| Tgene | AHR | C0027540 | Necrosis | 1 | CTD_human |
| Tgene | AHR | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| Tgene | AHR | C0027651 | Neoplasms | 1 | CTD_human |
| Tgene | AHR | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
| Tgene | AHR | C0028043 | Nicotine Dependence | 1 | CTD_human |
| Tgene | AHR | C0032285 | Pneumonia | 1 | CTD_human |
| Tgene | AHR | C0032300 | Lobar Pneumonia | 1 | CTD_human |
| Tgene | AHR | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | AHR | C0035334 | Retinitis Pigmentosa | 1 | ORPHANET |
| Tgene | AHR | C0037116 | Silicosis | 1 | CTD_human |
| Tgene | AHR | C0037997 | Splenic Diseases | 1 | CTD_human |
| Tgene | AHR | C0038002 | Splenomegaly | 1 | CTD_human |
| Tgene | AHR | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Tgene | AHR | C0039231 | Tachycardia | 1 | CTD_human |
| Tgene | AHR | C0040332 | Tobacco Dependence | 1 | CTD_human |
| Tgene | AHR | C0041955 | Ureteral Neoplasms | 1 | CTD_human |
| Tgene | AHR | C0042373 | Vascular Diseases | 1 | CTD_human |
| Tgene | AHR | C0080203 | Tachyarrhythmia | 1 | CTD_human |
| Tgene | AHR | C0086692 | Benign Neoplasm | 1 | CTD_human |
| Tgene | AHR | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| Tgene | AHR | C0153619 | Malignant neoplasm of ureter | 1 | CTD_human |
| Tgene | AHR | C0162351 | Contact hypersensitivity | 1 | CTD_human |
| Tgene | AHR | C0162834 | Hyperpigmentation | 1 | CTD_human |
| Tgene | AHR | C0236811 | Chronobiology Disorders | 1 | CTD_human |
| Tgene | AHR | C0239946 | Fibrosis, Liver | 1 | CTD_human |
| Tgene | AHR | C0242339 | Dyslipidemias | 1 | CTD_human |
| Tgene | AHR | C0242706 | Hyperoxia | 1 | CTD_human |
| Tgene | AHR | C0273115 | Lung Injury | 1 | CTD_human |
| Tgene | AHR | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Tgene | AHR | C0376384 | Nicotine Use Disorder | 1 | CTD_human |
| Tgene | AHR | C0400966 | Non-alcoholic Fatty Liver Disease | 1 | CTD_human |
| Tgene | AHR | C0559470 | Allergy to peanuts | 1 | CTD_human |
| Tgene | AHR | C0598784 | Dyslipoproteinemias | 1 | CTD_human |
| Tgene | AHR | C0700501 | Congenital nystagmus | 1 | CTD_human |
| Tgene | AHR | C0813142 | Circadian Rhythm Disorders | 1 | CTD_human |
| Tgene | AHR | C0848676 | Subfertility, Male | 1 | CTD_human |
| Tgene | AHR | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| Tgene | AHR | C0887800 | Psychogenic Inversion of Circadian Rhythm | 1 | CTD_human |
| Tgene | AHR | C0887898 | Experimental Lung Inflammation | 1 | CTD_human |
| Tgene | AHR | C0917731 | Male sterility | 1 | CTD_human |
| Tgene | AHR | C0920563 | Insulin Sensitivity | 1 | CTD_human |
| Tgene | AHR | C0971858 | Arthritis, Collagen-Induced | 1 | CTD_human |
| Tgene | AHR | C0993582 | Arthritis, Experimental | 1 | CTD_human |
| Tgene | AHR | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| Tgene | AHR | C1383860 | Cardiac Hypertrophy | 1 | CTD_human |
| Tgene | AHR | C1563937 | Atherogenesis | 1 | CTD_human |
| Tgene | AHR | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| Tgene | AHR | C2350344 | Chronic Lung Injury | 1 | CTD_human |
| Tgene | AHR | C2673809 | Infantile nystagmus | 1 | GENOMICS_ENGLAND |
| Tgene | AHR | C2931037 | Pancreatic cancer, adult | 1 | CTD_human |
| Tgene | AHR | C3241937 | Nonalcoholic Steatohepatitis | 1 | CTD_human |
| Tgene | AHR | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| Tgene | AHR | C3714636 | Pneumonitis | 1 | CTD_human |
| Tgene | AHR | C3830362 | Early Pregnancy Loss | 1 | CTD_human |
| Tgene | AHR | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Tgene | AHR | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| Tgene | AHR | C4552766 | Miscarriage | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies